lyophilised powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-08 and is reviewed periodically as new material appears.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.
Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.
| Property | Value | Notes |
|---|---|---|
| Primary route studied | Intranasal | Also examined parenterally in animal work |
| Reported plasma half-life | Minutes to tens of minutes | Values vary widely between reports |
| Main model systems | Rodent behavioural and cell assays | Human trials are few and small |
| Principal proposed targets | GABA-A receptor, GABA transaminase | Monoamine and neurotrophic pathways also reported |
| Evidence grade | Preliminary | Limited independent replication |
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Removal of pathogens includes encapsulated bacteria, which reduces sepsis risk (see § Complications below). Removal of damaged erythrocytes reduces iron burden from heme via hepatosplenic recycling, which reduces sepsis risk (see Complications below). Removal of damaged erythrocytes continues healthy signaling to bone marrow, where erythropoiesis replaces red blood cells lost to wear and tear. In relation to the three facts above, the spleen misguidedly filters spherocytes – regardless of the age or functional status of the cell. The spleen is not dysfunctional itself when selecting spherocytes for destruction, as this is the regular function of the spleen both at an anatomic structure level, and at the molecular cellular level. At the anatomic level, the passage from the cords of Billroth into the sinusoids may be seen as a "bottleneck", where red blood cells need to be flexible in order to pass through. In HS, the erythrocytes fail to pass through fenestrations, and this is where resident splenic macrophages sample, or "bite", part of the stuck spherocytes' plasma membranes. The macrophages recognize that the spherocyte is not normal, and the macrophage is "programmed" to destroy irregularities filtered at the spleen from the blood. The resident splenic macrophages therefore phagocytose the spherocytes, causing extravascular hemolysis. This leads to both splenomegaly and anemia. Should this process continue unchecked chronically, inappropriate regulation of erythropoiesis leads to extramedullary hematopoiesis.
The yR design approach provides an unvarying reaction site with regard to both (a) distance between reactants and (b) sequence environment surrounding the reaction site. Furthermore, the intimate connection between the code and the BB on the oligo-BB moieties which are mixed combinatorially in a single pot confers a high fidelity to the encoding of the library. The code of the synthesized products, furthermore, is not preset, but rather is assembled combinatorially and synthesized in synchronicity with the innate product.
Although eating tainted beef can lead to New Variant Creutzfeldt-Jakob disease (the human variant of mad-cow disease, bovine spongiform encephalopathy), there is no known case of BSE having been transmitted through collagen products such as gelatine.
=== Special populations === In children and adolescents, fluoxetine is the antidepressant of choice due to tentative evidence favoring efficacy and tolerability. Evidence supporting an increased risk of major fetal malformations resulting from fluoxetine exposure is limited, although the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has warned prescribers and patients of the potential for fluoxetine exposure in the first trimester (during organogenesis, formation of the fetal organs) to cause a slight increase in the risk of congenital cardiac malformations in the newborn. Furthermore, an association between fluoxetine use during the first trimester and an increased risk of minor fetal malformations was observed in one study. However, a systematic review and meta-analysis of 21 studies—published in the Journal of Obstetrics and Gynaecology Canada—concluded, "the apparent increased risk of fetal cardiac malformations associated with maternal use of fluoxetine has recently been shown also in depressed women who deferred SSRI therapy in pregnancy, and therefore most probably reflects an ascertainment bias. Overall, women who are treated with fluoxetine during the first trimester of pregnancy do not appear to have an increased risk of major fetal malformations." Per the US Food and Drug Administration (FDA), infants exposed to SSRIs in late pregnancy may have an increased risk for persistent pulmonary hypertension of the newborn.
==== Other Alienizers ==== Gas Drinkers (ガスドリンカーズ, Gasu Dorinkāzu): Living robots from Planet Algol who appear exclusively in the film Tokusou Sentai Dekaranger The Movie: Full Blast Action. They steal the deadly Golden Snow virus, which transforms organic lifeforms into living robots like themselves, and use it on Planet Leslie in the hopes of selling the vaccine for exorbitant prices, only to be deleted by the Dekarangers. Algolian Winsky (アルゴル星人ウインスキー, Arugoru Seijin Uinsukī): A deranged member of the group who is deleted by Deka Blue. Winsky is voiced by Yoshinori Okamoto (岡本 美登, Okamoto Yoshinori), who also portrays his human form. Algolian Zeen (アルゴル星人ジーン, Arugoru Seijin Jīn): A female member of the group who is deleted by Deka Yellow and Pink. Zeen is voiced by Akiko Amamatsuri (天祭 揚子, Amamatsuri Akiko), who also portrays her human form. Algolian Brandel (アルゴル星人ブランデル, Arugoru Seijin Buranderu): A Gas Drinker who is deleted by Deka Green. Brandel is voiced by Maroshi Tamura (田村 円, Tamura Maroshi), who also portrays his human form. Algolian Volger (アルゴル星人ヴォルガー, Arugoru Seijin Vorugā): The leader of the Gas Drinkers and a practitioner of the space martial art Jaa Kune Do (ジャアクンドー, Jaa Kun Dō). He intimidates Marie Gold into helping him and the Gas Drinkers before turning her into a carrier for the Golden Snow virus when she betrays him.
Sources: en.wikipedia.org
Common side effects include low blood sugar, nausea, dizziness, abdominal pain, and pain at the site of injection. Gastrointestinal side-effects tend to be strongest at the beginning of treatment period and subside over time. Other serious side effects may include angioedema, pancreatitis, gallbladder disease, and kidney problems. Use in pregnancy and breastfeeding is of unclear safety. A boxed warning in the US prescribing information cautions that medullary thyroid cancers have been observed in rats treated with liraglutide, but it is "unknown whether liraglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans, as relevance to humans of such tumors in rodents has not been determined."
== Biodegradable implants == Zinc (Zn), alongside magnesium (Mg) and iron (Fe), constitutes one of the three families of biodegradable metals. Zinc, as an abundant trace element, ranks sixth among all the essential metallic elements crucial for sustaining life within the human body. Zinc exhibits an intermediate biodegradation rate, falling between that of Fe (relatively slow) and Mg (relatively high) which positions it as a promising material for use in biodegradable implants.
== Function == As well as C. maenas, CCAP has cardioacceleratory properties in Manduca sexta and Drosophila melanogaster; it is a highly conserved protein found in species as diverse as moths and fruit flies in addition to the crustacean it was originally identified in. Under specific conditions, CCAP has also been shown to induce cardiac reversal in M. sexta and D. melanogaster. Since CCAP was first identified and its possible role suggested, it has been proven it serves many other functions. It regulates release of adipokinetic hormone during sustained flight in L. migratoria. It is also important in metabolism and digestion in other species; CCAP is involved as a hormone in the cockroach Periplaneta americana by upregulating digestive hormones after the insect has fed on nutritional matter. In the crab Cancer borealis CCAP controls passage of food through the foregut by modulating the stomatogastric ganglion's pyloric rhythm. This suggests CCAP is involved primarily in movement of food along the gut, facilitating digestion by secretion of digestive hormones and increasing flow of blood. The effects of CCAP on the reproductive organs of females of the species L. migratoria have also been studied. The peptide stimulates the contraction of the oviducts and spermatheca. There is no CCAP or CCAP-like immunoreactivity shown in the oviduct or the nerves innervating the oviduct so it is probable that CCAP acts as a neurohormone to perform these functions. CCAP is one of several peptides and hormones to be involved in the moulting process of crustaceans and insects.
== Signs and symptoms == For unknown reasons, children born with FOP often have malformed big toes, sometimes missing a joint or, in other cases, simply presenting with a notable lump at the minor joint. The first "flare-up" that leads to the formation of FOP bone usually occurs before the age of 10. The bone growth generally progresses from the top of the body downward, just as bones grow in fetuses. A child with FOP will typically develop additional bones starting at the neck, then at the shoulders, arms, chest area, and finally at the feet. Specifically, ossification is typically first seen in the dorsal, axial, cranial, and proximal regions of the body. Later, the disease progresses in the ventral, appendicular, caudal, and distal regions. However, it does not necessarily occur in this order due to injury-caused flare-ups. Often, the tumor-like lumps that characterize a flare-up of the disease appear suddenly. Bone growth occurring during flare-ups may result in the loss of mobility to affected joints, including, if the jaw/mandible is involved, the inability to fully open the mouth, limiting speech and eating. Bone growth can also result in the immobilization of the hip or knee, affecting the individual's ability to walk. Extra bone formation around the rib cage restricts the expansion of lungs and diaphragm causing respiratory complications. Since the disorder is incredibly rare, only occurring in 1 out of 2 million people, the condition may be misdiagnosed as cancer or fibrosis.
== History == In 1987, Dynacare Health Group acquired its first diagnostic laboratory—Quality Medical Laboratories and established Dynacare Laboratories. By 2015, Dynacare was part of the Central Medical Laboratories (CML), established in 1959 in Winnipeg, Manitoba. Dynacare was formed with the formation of an "operational partnership" in 1997 between Ontario's Bio-Science Laboratory and Gamma North Peel Partnership Inc. In 2002, Laboratory Corporation of America (LabCorp) acquired Dynacare Laboratories—one of the Dynacare partners—for US$480-million, while also assuming Dynacare debt worth $205-million. By 2002, Dynacare, just before LabCorp's takeover, had become the largest central clinical laboratory in western Canada, with a revenue in 2001 of $402.4-million and a profit of $11.7-million. By June 2020, DynaLIFE was operating 36 private laboratories in the Edmonton area and northern Alberta and had a contract with the Alberta government that is set to expire in 2022. In June 2020, Alberta Health Services, announced plans to outsource public community laboratory services to private companies. Gamma-Dynacare acquired LifeLabs Quebec. In 2013, DynaLIFE Medical Labs partnered with Dynacare, which operates laboratories in Alberta and across Canada. In 2015, Gamma-Dynacare Medical Laboratories rebranded itself back to Dynacare.
Sources: en.wikipedia.org
The following is a list of women who have been elected or appointed head of state or government of their respective countries. The first list includes female presidents who are heads of state and may also be heads of government, as well as female heads of government who are not concurrently head of state, such as prime ministers. The list does not include Queens regnant who are heads of state (but not of government). Khertek Anchimaa, of the mostly unrecognized and now defunct Tuvan People's Republic, is regarded as the first elected female head of state in the world, although not in multiparty, free and fair elections. The wife of the nation's Supreme Leader, she is the first woman to be elected chairman of a country. She became the chairwoman of the country's presidium in 1940. The first woman to be elected as prime minister of a country was Sirimavo Bandaranaike of Ceylon (present-day Sri Lanka), when she led her party to victory in the July 1960 general election. The first woman to serve as president of a country was Isabel Perón of Argentina, who served as the country's vice president and succeeded to the presidency in July 1974 upon the death of her husband. In 1979, Margaret Thatcher was elected as Prime Minister of the United Kingdom, becoming both the United Kingdom's first female prime minister, and Europe's first elected female head of government.
Inspection focuses on the face and particularly on the tongue, including analysis of the tongue size, shape, tension, color and coating, and the absence or presence of teeth marks around the edge. Auscultation refers to listening for particular sounds (such as wheezing). Olfaction refers to attending to body odor. Inquiry focuses on the "seven inquiries", which involve asking the person about the regularity, severity, or other characteristics of: chills, fever, perspiration, appetite, thirst, taste, defecation, urination, pain, sleep, menses, leukorrhea. Palpation which includes feeling the body for tender A-shi points, and the palpation of the wrist pulses as well as various other pulses, and palpation of the abdomen.
Even though the original relation was based on studies of spruce, Hankinson's equation has been found to be remarkably accurate for many other types of wood. A generalized form of the Hankinson formula has also been used for predicting the uniaxial tensile strength of wood at an angle to the grain. This formula has the form
== Education == Nuzzo graduated from the University of South Florida with a bachelor's degree in industrial engineering and went on to obtain her Ph.D in statistics from Stanford University in 2004, supervised by Richard A. Olshen. Her dissertation was written on the usage of stochastic models in biochemistry. Nuzzo also graduated from the University of California Santa Cruz's science writing program.
== Hosts and disease development == Penicillium expansum has a wide host range, causing similar symptoms on fruits which include apples, pears, cherries, and citrus. Initial infection most often occurs at sites of fruit injury, such as bruises or puncture wounds. Although infections may start in the field, infected spots often become evident post-harvest, and expand while fruit is in storage. Infected areas are clearly delineated and light brown, and soft decaying tissue can be easily "scooped" out of the surrounding healthy tissue. Spore masses later appear on the surfaces of infected fruit, initially appearing as white mycelium, then turning blue to blue-green in color as the asexual spores mature. Fruit affected by P. expansum typically has an earthy, musty odor. Lesions measure 1–1.25 inches in diameter eight to ten weeks after infection if kept under cold storage conditions. Age factors into P. expansum infection, in that overripe or mature fruits are most susceptible to infection, while those picked underripe are less likely to become infected. In apples, the colors of the lesions may vary with variety, from lighter-brown on green and yellow apple varieties, to dark-brown on the deeper-red and other darker-color varieties. Varieties particularly susceptible to P. expansum infection include McIntosh, Golden Supreme, and Golden Delicious. Both sweet and sour cherries are affected by P. expansum. Cherry varieties found to be particularly susceptible to P. expansum infection were mainly early varieties, including Navalinda and Burlat.
Sources: en.wikipedia.org
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.
The peptide enters plasma rapidly and is broken down by ordinary proteases into amino acids and shorter fragments. Reported half-lives are short. Whether meaningful amounts of the intact molecule reach the brain is an open question.
Most clinical reports are small, published in Russian and not independently replicated. English-language reviews highlight the absence of large randomised trials. Conclusions about efficacy should be treated as provisional.
Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.